X4 Pharmaceuticals, Inc Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2017 to Q2 2024

Taxonomy & unit: us-gaap: USD
Description: Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary: X4 Pharmaceuticals, Inc quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2017 to Q2 2024.
X4 Pharmaceuticals, Inc Share-based Payment Arrangement, Expense for the quarter ending June 30, 2024 was $2.43M, a 13.4% increase year-over-year.
X4 Pharmaceuticals, Inc Share-based Payment Arrangement, Expense for the twelve months ending June 30, 2024 was $9.07M, a 51% increase year-over-year.
X4 Pharmaceuticals, Inc annual Share-based Payment Arrangement, Expense for 2023 was $8.69M, a 67.1% increase from 2022.
X4 Pharmaceuticals, Inc annual Share-based Payment Arrangement, Expense for 2022 was $5.2M, a 15.9% decline from 2021.
X4 Pharmaceuticals, Inc annual Share-based Payment Arrangement, Expense for 2021 was $6.18M, a 13.9% increase from 2020.

Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)

Share-based Payment Arrangement, Expense, Quarterly (USD)

Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)

Period	TTM Value	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed
Q2 2024	$9.07M	$2.43M	+$286K	+13.4%	Apr 1, 2024	Jun 30, 2024	10-Q	2024-08-08
Q1 2024	$8.78M	$1.74M	+$94K	+5.71%	Jan 1, 2024	Mar 31, 2024	10-Q	2024-05-07
Q4 2023	$8.69M	$2.54M	+$1.43M	+129%	Oct 1, 2023	Dec 31, 2023	10-K	2024-03-21
Q3 2023	$7.26M	$2.36M	+$1.25M	+113%	Jul 1, 2023	Sep 30, 2023	10-Q	2023-11-09
Q2 2023	$6.01M	$2.14M	+$620K	+40.7%	Apr 1, 2023	Jun 30, 2023	10-Q	2024-08-08
Q1 2023	$5.39M	$1.65M	+$186K	+12.7%	Jan 1, 2023	Mar 31, 2023	10-Q	2024-05-07
Q4 2022	$5.2M	$1.11M	-$502K	-31.2%	Oct 1, 2022	Dec 31, 2022	10-K	2024-03-21
Q3 2022	$5.7M	$1.11M	-$405K	-26.7%	Jul 1, 2022	Sep 30, 2022	10-Q	2023-11-09
Q2 2022	$6.11M	$1.52M	-$275K	-15.3%	Apr 1, 2022	Jun 30, 2022	10-Q	2023-08-10
Q1 2022	$6.38M	$1.46M	+$201K	+16%	Jan 1, 2022	Mar 31, 2022	10-Q	2023-05-04
Q4 2021	$6.18M	$1.61M	+$211K	+15.1%	Oct 1, 2021	Dec 31, 2021	10-K	2024-03-21
Q3 2021	$5.97M	$1.52M	-$728K	-32.4%	Jul 1, 2021	Sep 30, 2021	10-Q	2022-11-03
Q2 2021	$6.7M	$1.8M	+$624K	+53.2%	Apr 1, 2021	Jun 30, 2021	10-Q	2022-08-04
Q1 2021	$6.07M	$1.26M	+$645K	+105%	Jan 1, 2021	Mar 31, 2021	10-Q	2022-05-12
Q4 2020	$5.43M	$1.4M	+$734K	+111%	Oct 1, 2020	Dec 31, 2020	10-K	2023-03-21
Q3 2020	$4.69M	$2.24M	+$1.55M	+225%	Jul 1, 2020	Sep 30, 2020	10-Q	2021-11-04
Q2 2020	$3.14M	$1.17M	+$740K	+171%	Apr 1, 2020	Jun 30, 2020	10-Q	2021-08-03
Q1 2020	$2.4M	$613K	+$351K	+134%	Jan 1, 2020	Mar 31, 2020	10-Q	2021-05-06
Q4 2019	$2.05M	$664K	+$376K	+131%	Oct 1, 2019	Dec 31, 2019	10-K	2022-03-17
Q3 2019	$1.67M	$691K	+$493K	+249%	Jul 1, 2019	Sep 30, 2019	10-Q	2020-11-05
Q2 2019	$1.18M	$433K	+$288K	+199%	Apr 1, 2019	Jun 30, 2019	10-Q	2020-08-04
Q1 2019	$893K	$262K	+$134K	+105%	Jan 1, 2019	Mar 31, 2019	10-Q	2020-05-07
Q4 2018	$759K	$288K	+$423K		Oct 1, 2018	Dec 31, 2018	10-K	2021-03-19
Q3 2018	$336K	$198K	-$75K	-27.5%	Jul 1, 2018	Sep 30, 2018	10-Q	2019-11-07
Q2 2018	$411K	$145K	-$27K	-15.7%	Apr 1, 2018	Jun 30, 2018	10-Q	2019-08-07
Q1 2018	$438K	$128K	-$54K	-29.7%	Jan 1, 2018	Mar 31, 2018	10-Q	2019-05-15
Q4 2017	$492K	-$135K			Oct 1, 2017	Dec 31, 2017	10-K	2020-03-12
Q3 2017		$273K			Jul 1, 2017	Sep 30, 2017	10-Q	2018-11-09
Q2 2017		$172K			Apr 1, 2017	Jun 30, 2017	10-Q	2018-08-13
Q1 2017		$182K			Jan 1, 2017	Mar 31, 2017	10-Q	2018-05-10

* An asterisk sign (*) next to the value indicates that the value is likely invalid.